Sold as Nextstellis. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Drospirenone; Estetrol (sold as Nextstellis), first approved Apr 15, 2021, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Nextstellis | Part D | $142K | +52% | 107 |
| Arterial Vascular Effects of Estetrol-drospirenone Combined Oral Contraceptive PillContraception · Dr. Hang Wun Raymond Li | Phase 3 | Not yet recruiting | Apr 17, 2026 |
| Prospective Evaluation on the Role Exerted by Hormonal Contraceptives on 24-h Blood Pressure. A Prospective Observational StudyCardiovascular System Diseases (&Amp; [Cardiac]) · Ospedale Policlinico San Martino | — | Recruiting | Jul 11, 2025 |
| International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)Contraception · Center for Epidemiology and Health Research, Germany | — | Recruiting | Dec 29, 2023 |
| International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety StudyContraception, Birth Control · Center for Epidemiology and Health Research, Germany | — | Recruiting | Sep 8, 2023 |
| Estetrol/Drospirenone to Reduce the Average Size of EndometriomasOvarian Endometrioma, Endometrioma · Andrew Zakhari | Phase 4 | Recruiting | May 1, 2023 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Apr 15, 2021 | NextstellisNDA 214154 · New molecular entity, new combination | Mayne Pharma | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA